ACP-01 Phase II Clinical Trial for CLI

ACP-01 Phase II Clinical Trial

Hemostemix is currently conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial for patients with critical limb ischemia at sites in the Canada and United States.

33 control

66 treated

Target Patients

  • Diagnosed with CLI
  • No treatment options
  • Controlled levels in blood sugar, blood pressure, cholesterol
  • No previous amputations above the ankle on target limb

Data collection

 



adverse
events

treatment
failure¹

pain

quality
of life

 

¹Clinical endpoints, as defined by treatment failure, are major amputation (above the talus, 2x wound size, de novo gangrene

 

How to Participate in the ACP-01 Clinical Trial

For information about participating in the clinical trial please contact

Catherine St George
Clinical Trial Manager
cstgeorge@hemostemix.com